Personalized Cancer Vaccine Summit
Evvnt Promotion / evvnt
Archivo
03.12.2024 - 05.12.2024 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
Temas de la conferencia
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Observaciones
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832
Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832
Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more
Información e inscripción:
https://go.evvnt.com/2558274-2?pid=4832
Ms. Isabel Weir
Oncología
Idioma
Inglés
Inglés
Cuota del Congreso
USD 2599.00 - USD 5097.00
USD 2599.00 - USD 5097.00
Los participantes esperaban
1000 - 1000
1000 - 1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
